Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)

Type: Poster Session

Time: Saturday June 1, 8:00 AM to 11:00 AM

Location: Hall A

Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.

Sub-category:
Circulating Biomarkers

Category:
Developmental Therapeutics and Tumor Biology (Nonimmuno)

Meeting:
2019 ASCO Annual Meeting

Abstract No:
3046

Poster Board Number:
Poster Session (Board #38)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 3046)

Author(s): Yuichi Kumaki, Sadakatsu Ikeda, Thereasa A. Rich, Jing Zhao, Takayuki Yoshino, Byoung Chul Cho, Nir Peled, Ji-Youn Han, Yukimasa Shiotsu, Aleksandra Franovic, Victoria M. Raymond, Razelle Kurzrock, Richard B. Lanman, Jeeyun Lee, Tony S. K. Mok; Tokyo Medical and Dental University, Tokyo, Japan; Guardant Health, Redwood City, CA; Guardant Health, Inc, Redwood City, CA; National Cancer Center Hospital East, Kashiwa, Japan; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Clalit Health Services, Soroka Medical Center, Beer-Sheeva, Israel; Center for Lung Cancer, National Cancer Center, Gyeonggi-Do, South Korea; Guardant Health, Inc., Redwood City, CA; University of California San Diego, Moores Cancer Center, La Jolla, CA; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Prince of Wales Hospital, Hong Kong, China

Abstract Disclosures

Abstract:

Background: MET amps can occur from focal gene copy number gain (e.g. MET-driven) or gain of chromosome 7 (e.g. aneuploidy); however, the contribution of each to MET amp is not well established. MET inhibitor-sensitive lung cancers harboring high-level MET amp have been reported in the absence of other sensitizing MET alterations (alts), e.g. exon 14 skipping, particularly among those with higher MET to chromosome 7 ratios. Methods: 3,114 samples from 2,902 Asian patients with advanced solid tumors were tested with a comprehensive cfDNA NGS panel (Guardant360) between Oct 2015-Dec 2018. This 70-73 gene assay evaluates single nucleotide variants (SNV), selected insertion-deletions (indels), fusions, and copy number gains. Focal amp was determined bioinformatically as having statistically higher copy number relative to other genes, such as BRAF, or CDK6, in the same chromosome arm. Results: MET alts associated with aberrant signaling were found in 223 pts (7.7%) with 18 different cancer types, most commonly lung (128/1,678), colorectal (36/349), and prostate (11/48). Among 223 pts, 189 pts (84.8%) had amps, 38(17.0%) had exon 14 skipping, and 8 (3.6%) had activating SNVs. 39.7% of MET amp was focal but differed by cancer type; highest prevalence was in gastroesophageal (80%) and lowest in prostate cancers (9%). Samples with focal MET amp had higher plasma copy number compared to those with non-focal MET amp (mean 5.8 vs. 2.5; p < 0.0001) and lower total number of alts per sample (8.8 vs. 11; p = 0.0122). Focal MET amp was more common than non-focal MET amp among 419 EGFR mutated samples (6.9% vs. 3.8%, p = 0.05) suggesting focal MET amp may be biologically more relevant as a mechanism of EGFR TKI resistance. Conclusions: This is the first study to use cfDNA to examine focal vs. non-focal MET amp. Focal MET amp accounted for ~40% of all MET amps, was found in 2.6% of pts with diverse cancers, was associated with higher plasma copy number, and found in a higher proportion of EGFR mutated lung cancer samples. The ability to differentiate may be clinically relevant given higher MET to chromosome 7 ratios have been associated with improved therapeutic response.

 
Other Abstracts in this Sub-Category:

 

1. Genome-wide cell-free DNA fragmentation profiling for early cancer detection.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3018 First Author: Alessandro Leal
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - Circulating Biomarkers

 

2. Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3019 First Author: Jean-Yves Pierga
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - Circulating Biomarkers

 

3. Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3020 First Author: Ugo De Giorgi
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - Circulating Biomarkers

 

More...